<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769184</url>
  </required_header>
  <id_info>
    <org_study_id>08-LCDSTRD</org_study_id>
    <nct_id>NCT00769184</nct_id>
  </id_info>
  <brief_title>Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis</brief_title>
  <official_title>A Steroid-Sparing Effect of Supplemental LCD Treatment in Patients With Moderate-to-Severe Localized Psoriasis Lesions: a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoStrata Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoStrata Company, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of
      follow-up. The purpose of the study is to compare the safety and effectiveness of combining
      and then following a high potency topical corticosteroid treatment with LCD treatment for
      moderate-to-severe localized plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Superpotent topical corticosteroids such as clobetasol propionate are highly effective in
      treating plaque psoriasis but are not indicated for long term use due to their side effects.
      Therefore, steroid-sparing combination and sequential regimens, in which the corticosteroid
      gets supplemented with a non-steroid medication, such as calcipotriol or tazarotene, have
      become the standard of care, especially in the management of localized psoriasis lesions. A
      new steroid-free 15% liquor carbonis distillate (LCD) solution (Psorent) was recently found
      to be more successful than 0.005% calcipotriol cream (Dovonex) at improving and delaying
      worsening of psoriasis symptoms in a controlled clinical trial. The goal of this pilot study
      is to evaluate if this LCD solution can be used in combination with acute topical
      corticosteroid therapy as a new steroid-sparing / enhancing regimen. We hope to explore the
      compatibility, patient tolerability, and clinical benefit of using LCD solution during and
      after treatment with clobetasol propionate in adults with moderate to severe plaque
      psoriasis. This is a randomized, double-blind, vehicle-controlled, bilateral study. Men and
      women 18 years of age or older, with chronic plaque psoriasis affecting less than or equal to
      10% body surface area (BSA) in areas other than the scalp, face, palms, soles, axillae, and
      groin, are recruited. Those with a Physician Global Assessment (PGA) score greater than 3 and
      are in general good health will qualify as candidates. On one side of the body, LCD solution
      and clobetasol propionate will be administered twice daily for the first 2 weeks of
      treatment, followed by 4 weeks of LCD solution only, followed by 6 weeks of no treatment. On
      the second half of the body, subject will apply a vehicle solution and clobetasol propionate
      twice daily for the first 2 weeks, only the vehicle solution twice daily for the next four
      weeks, and then no treatment for the next 6 weeks. Subjects will be evaluated at weeks 2, 4,
      6, 8, 10 and 12. investigators will use the PGA scale [Clear (0) - Severe (5)] to determine
      treatment effects as well as Target Lesion assessments of Erythema, Scaling, Induration and
      overall severity [None (0) - Very Severe (4)]. patients will also be required to complete
      Self-Assessment questionnaires on their psoriasis [None (0) - Severe (6)]. as well as an
      assessment of the study solution [Excellent (9) - Poor (1)]. . Photographs will be taken at
      each study visit and adverse events will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit.</measure>
    <time_frame>Weeks 2, 6, &amp; 12.</time_frame>
    <description>Those patients that have reached a PGA score of zero [PGA scale: clear (0) - very severe (5)], and are considered clear of chronic plaque psoriasis, or have reached a PGA score of 1, with minimal disease at each visit, in each condition. Data was collected at weeks 2, 6 and 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Improvement in Disease Severity Using PGA and OTLS Scores of Target Lesions</measure>
    <time_frame>Weeks 2, 6, &amp; 12</time_frame>
    <description>Mean percent improvement in disease severity using Physician Global Assessment (PGA) [PGA scale: Clear (0) - Very Severe (5)] and overall severity scores of target lesions (OTLS) [OTLS scale None (0) - Very Severe (4)] based on erythema, scaling and induration, at each visit interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Corticosteroid + LCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>One side of body:
clobetasol: 2 applications / day along with LCD application 2 applications/day</description>
    <arm_group_label>Corticosteroid + LCD</arm_group_label>
    <arm_group_label>Corticosteroid + Placebo</arm_group_label>
    <other_name>clobetasol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One side of body:
Placebo Solution: 2 applications / day along with clobetasol 2 applications/day</description>
    <arm_group_label>Corticosteroid + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCD</intervention_name>
    <description>One side of body:
LCD Solution: 2 applications / day along with clobetasol 2 applications/day</description>
    <arm_group_label>Corticosteroid + LCD</arm_group_label>
    <other_name>liquor carbonis distillate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  able to provide written informed consent

          -  able to attend study visits, apply medications, and follow instructions

          -  moderate to severe localized plaque psoriasis lesions (&lt;10% BSA on each side of the
             body)

        Exclusion Criteria:

          -  other current treatments for psoriasis

          -  hypersensitivity to steroids, liquor carbonis detergens, alcohol, fragrance

          -  pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Bagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psoriasis Treatment Center of Central New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Windsor Dermatology</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <results_first_submitted>November 14, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2015</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Corticosteroid + LCD (Left), Corticosteroid + Placebo (Right)</title>
          <description>Corticosteroid + LCD on left side of body, Corticosteroid + Placebo on right side of body (n=7).
On left side: Corticosteroid + liquor carbonis distillate (LCD) treatment applied, twice a day, for 2 weeks, then LCD-only, twice a day, for 4 weeks, then no treatment for 6 weeks
On right side: Corticosteroid and placebo vehicle solution, twice a day, for 2 weeks, then placebo vehicle solution-only, twice a day, for 4 weeks, then no treatment for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Corticosteroid + LCD (Right), Corticosteroid + Placebo (Left)</title>
          <description>Corticosteroid + LCD on right side of body, Corticosteroid + Placebo on left side of body (n=8).
On right side: Corticosteroid + liquor carbonis distillate (LCD) treatment applied, twice a day, for 2 weeks, then LCD-only, twice a day, for 4 weeks, then no treatment for 6 weeks
On left side: Corticosteroid and placebo vehicle solution, twice a day, for 2 weeks, then placebo vehicle solution-only, twice a day, for 4 weeks, then no treatment for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Corticosteroid + LCD/ +Placebo (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>+LCD / +Placebo Only (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>No Treatment (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fifteen patients with localized chronic plaque psoriasis (less than or equal to 6% BSA and PGA score greater than or equal to 3) were enrolled. Eleven patients completed the study. Three patients were removed due to an adverse event, and 1 patient was lost to follow-up after week 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Corticosteroid+LCD vs Corticosteroid+Placebo</title>
          <description>one side of body: corticosteroid and liquor carbonis distillate (LCD) treatment applied twice a day, for 2 weeks, then LCD-only twice a day, for 4 weeks, then no treatment for 6 weeks
opposite side of body: corticosteroid and placebo vehicle solution twice a day, for 2 weeks, then placebo vehicle solution-only twice a day, for 4 weeks, then no treatment for 6 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit.</title>
        <description>Those patients that have reached a PGA score of zero [PGA scale: clear (0) - very severe (5)], and are considered clear of chronic plaque psoriasis, or have reached a PGA score of 1, with minimal disease at each visit, in each condition. Data was collected at weeks 2, 6 and 12.</description>
        <time_frame>Weeks 2, 6, &amp; 12.</time_frame>
        <population>All randomized patients were included in analyses. Missing scores within each study phase only were filled in by last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Corticosteroid + LCD</title>
            <description>Corticosteroid + LCD solution applied to one side of body twice per day for 2 weeks. Then, LCD solution- only applied to one side of the body twice per day for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid + Placebo</title>
            <description>Corticosteroid + placebo applied to one side of body twice per day for 2 weeks. Then, placebo-only applied to one side of the body twice per day for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit.</title>
          <description>Those patients that have reached a PGA score of zero [PGA scale: clear (0) - very severe (5)], and are considered clear of chronic plaque psoriasis, or have reached a PGA score of 1, with minimal disease at each visit, in each condition. Data was collected at weeks 2, 6 and 12.</description>
          <population>All randomized patients were included in analyses. Missing scores within each study phase only were filled in by last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage with PGA scores ≤ 1 at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage with PGA scores ≤ 1 at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage with PGA scores ≤ 1 at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Improvement in Disease Severity Using PGA and OTLS Scores of Target Lesions</title>
        <description>Mean percent improvement in disease severity using Physician Global Assessment (PGA) [PGA scale: Clear (0) - Very Severe (5)] and overall severity scores of target lesions (OTLS) [OTLS scale None (0) - Very Severe (4)] based on erythema, scaling and induration, at each visit interval.</description>
        <time_frame>Weeks 2, 6, &amp; 12</time_frame>
        <population>All randomized patients were included in analyses. Missing scores within each study phase only were filled in by last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Corticosteroid + LCD</title>
            <description>Corticosteroid + LCD solution applied to one side of body twice per day for 2 weeks. Then, LCD solution-only applied to one side of the body twice per day for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid + Placebo</title>
            <description>Corticosteroid + placebo solution applied to one side of body twice per day for 2 weeks. Then, placebo-only applied to one side of the body twice per day for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Improvement in Disease Severity Using PGA and OTLS Scores of Target Lesions</title>
          <description>Mean percent improvement in disease severity using Physician Global Assessment (PGA) [PGA scale: Clear (0) - Very Severe (5)] and overall severity scores of target lesions (OTLS) [OTLS scale None (0) - Very Severe (4)] based on erythema, scaling and induration, at each visit interval.</description>
          <population>All randomized patients were included in analyses. Missing scores within each study phase only were filled in by last observation carried forward.</population>
          <units>Mean Percent Improvement</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent improvement of PGA score at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="26" upper_limit="58"/>
                    <measurement group_id="O2" value="34" lower_limit="25" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent improvement of PGA score at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="34" upper_limit="72"/>
                    <measurement group_id="O2" value="25" lower_limit="10" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent improvement of PGA score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="14" upper_limit="61"/>
                    <measurement group_id="O2" value="12" lower_limit="-6" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent improvement of OTLS score at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="31" upper_limit="59"/>
                    <measurement group_id="O2" value="43" lower_limit="32" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent improvement of OTLS score at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="38" upper_limit="68"/>
                    <measurement group_id="O2" value="20" lower_limit="19" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent improvement of OTLS score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="14" upper_limit="56"/>
                    <measurement group_id="O2" value="7" lower_limit="4" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event information was monitored throughout the entire 12 week study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Corticosteroid + LCD</title>
          <description>Corticosteroid + LCD solution applied to one side of body twice per day for 2 weeks. Then, LCD solution- only applied to one side of the body twice per day for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Corticosteroid + Placebo</title>
          <description>Corticosteroid + placebo applied to one side of body twice per day for 2 weeks. Then, placebo-only applied to one side of the body twice per day for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contact Dermatitis</sub_title>
                <description>One subject was removed from the study due to a treatment-related adverse event involving contact dermatitis with clobetasol, LCD, and vehicle with bilateral itching.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bilateral Worsening of Plaque Psoriasis</sub_title>
                <description>Two subjects were removed from the study due to treatment-related bilateral worsening of their psoriasis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a bilateral study in which 15 subjects total were recruited and randomized to receive both interventions simultaneously by dividing treatment arms to each side of the body.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Barbara Green, RPH, MS</name_or_title>
      <organization>NeoStrata Co., Inc.</organization>
      <phone>(609) 520-0715</phone>
      <email>bgreen@neostrata.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

